Objectives

After participating in this educational activity, attendees should be able to:

1| Evaluate the impact of hydroxyurea therapy on organ-specific morbidity in patients with Sickle Cell Disease (SCD)
2| Explore the emerging role of gene editing in SCD
 
Presenter(s): 
Tasneem Baker, PharmD
PGY1 Pharmacy Resident
Baystate Medical Center
 
NameRoleFinancial Relationship DisclosuresDiscussion of
Unlabeled/Unapproved Uses of
Drugs/Devices in Presentation?
Tasneem Baker, PharmDSpeaker/AuthorNo relevant relationships with ineligible companies to discloseNo
Session date: 
04/14/2025 - 2:00pm to 3:00pm EDT
Add to calendar: 
  • 1.00 ACPE Contact Hours
  • 1.00 ACPE Technician contact hours

Please login or register to take this course.